IPO
Company Profile
Attovia Therapeutics is a clinical-stage biotech developing ATTOBODY-based biotherapeutics for immune-mediated diseases that went public on Nasdaq in August 2026 in an upsized IPO raising ~$332M gross.
Founded 2023San Carlos, CAATTO~$588M ($256M private + $332M IPO gross incl. greenshoe, Aug 2026) raised$767M at IPO pricing; ~$904M market cap at Nasdaq open (Aug 5, 2026) valuation
Investors
venBio PartnersGoldman Sachs AlternativesFrazier Life SciencesDeep Track CapitalIllumina VenturesSanofi VenturesEcoR1 Capital
Compare with
Funding & Valuation History
from our coverage| Date | Event | Amount | Valuation | Source |
|---|---|---|---|---|
| Aug 5, 2026 | IPO (Nasdaq: ATTO, 17M shares at $17, upsized) | $289M | $767M | — |
| Apr 15, 2025 | Series C | $90M | — | — |
| Jun 1, 2023 | Series A | $60M | — | — |
Attovia Therapeutics FAQ
- What is Attovia Therapeutics's valuation in 2026?
- Attovia Therapeutics is publicly traded under the ticker ATTO with a market capitalization of about $767M at IPO pricing; ~$904M market cap at Nasdaq open (Aug 5, 2026).
- How much has Attovia Therapeutics raised?
- Attovia Therapeutics has raised approximately ~$588M ($256M private + $332M IPO gross incl. greenshoe, Aug 2026) in total funding to date.
- Is Attovia Therapeutics publicly traded?
- Yes. Attovia Therapeutics trades under the ticker ATTO.
- Who are Attovia Therapeutics's investors?
- Attovia Therapeutics's investors include venBio Partners, Goldman Sachs Alternatives, Frazier Life Sciences, Deep Track Capital, Illumina Ventures, Sanofi Ventures, EcoR1 Capital.
Coverage Timeline
newest first- Aug 10, 2026IPOBiotech IPO Window Closes Its Strongest Week Since Spring~$972M, 4 deals→
- Aug 10, 2026IPOAttovia Therapeutics Climbs 29% After $289M IPO$289M IPO→
- Aug 5, 2026IPOGoldman-Backed Attovia Prices IPO, Lists on Nasdaq~$212.5M raised→
- Aug 5, 2026IPOAttovia Prices $289M Nasdaq IPO at $17 a Share$289M IPO→
- Aug 4, 2026IPOAttovia Prices IPO as Biotech's Public Pipeline Fills Out$17/share IPO→
- Jul 29, 2026IPOGoldman-Backed Attovia Sets Terms for $200M Nasdaq IPO$200M target IPO→
- Jul 29, 2026IPOGoldman-Backed Attovia Seeks $212.5M in Biotech IPO$212.5M IPO→
- Jul 14, 2026IPOTwo New Biotech IPO Filings Land in One Week2 S-1s, same week→
All Coverage
IPO~$972M, 4 deals
Biotech IPO Window Closes Its Strongest Week Since Spring
BlossomHill and Latigo Biotherapeutics both closed upsized IPOs by August 10, capping a four-deal stretch that also included Braveheart Bio and Attovia Therapeutics pricing above or near the top of their ranges.
FOLLOW-UP
IPO
Attovia Therapeutics Climbs 29% After $289M IPO
IPO$289M IPO
Attovia Therapeutics Climbs 29% After $289M IPO
Attovia Therapeutics priced an upsized $289 million IPO and climbed 29% on debut, the fourth biotech in two weeks to price well above its original terms.
FOLLOW-UP
IPO
Goldman-Backed Attovia Prices IPO, Lists on Nasdaq
IPO~$212.5M raised
Goldman-Backed Attovia Prices IPO, Lists on Nasdaq
Attovia Therapeutics priced its IPO at $17/share, raising roughly $212.5M, and began trading on Nasdaq today under ATTO -- another test of whether biotech's IPO window is genuinely reopening.
IPO
Attovia Prices $289M Nasdaq IPO at $17 a Share
IPO$289M IPO
Attovia Prices $289M Nasdaq IPO at $17 a Share
Attovia Therapeutics priced 17 million shares at $17 to raise $289M on Nasdaq under the ticker ATTO, the largest operating-company listing of the first week of August.
IPO
Attovia Prices IPO as Biotech's Public Pipeline Fills Out
IPO$17/share IPO
Attovia Prices IPO as Biotech's Public Pipeline Fills Out
Attovia Therapeutics priced its Nasdaq IPO at $17 a share while Latigo Biotherapeutics advances its own S-1, the latest signs that the biotech listing window is filling with genuine clinical-stage pipelines.
IPO
Goldman-Backed Attovia Sets Terms for $200M Nasdaq IPO
IPO$200M target IPO
Goldman-Backed Attovia Sets Terms for $200M Nasdaq IPO
Attovia Therapeutics set terms for a Nasdaq IPO, offering 12.5 million shares at $15-17 to raise up to $212.5 million, advancing its Phase 1 itch and eczema drug candidates toward a public listing under ticker ATTO.
IPO
Goldman-Backed Attovia Seeks $212.5M in Biotech IPO
IPO$212.5M IPO
Goldman-Backed Attovia Seeks $212.5M in Biotech IPO
Attovia Therapeutics is seeking up to $212.5 million in a US IPO, offering 12.5 million shares at $15-$17 each, backed by Goldman Sachs Alternatives, Deep Track Capital, Frazier Life Sciences, and venBio.
IPO
Two New Biotech IPO Filings Land in One Week
IPO2 S-1s, same week
Two New Biotech IPO Filings Land in One Week
Braveheart Bio and Attovia Therapeutics both filed S-1s the same week, adding two names to 2026's biotech IPO pipeline amid the strongest H1 biotech venture funding since 2022.